Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a pioneering biotechnology holding company dedicated to advancing regenerative medicine. Headquartered in Phoenix, Arizona, the company was incorporated in 1998 and operates as a subsidiary of Creative Medical Health, Inc. It leverages innovative stem cell research to develop therapeutic applications aimed at treating male and female sexual dysfunction, infertility, miscarriages, and related health issues.
The company's flagship product, marketed under the brand name CaverStem, specifically addresses erectile dysfunction (ED). CaverStem is offered to physicians to help patients suffering from ED through stem cell-based therapies.
In recent developments, Creative Medical Technology Holdings has seen notable success in the allogeneic cell therapy market. In Q4 2022, the company unveiled the development of AlloStem™, a cell line derived from human perinatal tissue, which incorporates a Master Cell Bank and a Drug Master File. The FDA has granted approval for the CELZ-201 program, allowing it to be used in early clinical trials for type 1 diabetes. The AlloStem™ line is also being employed in the company's StemSpine® procedure to treat chronic back pain, demonstrating significant reductions in narcotic usage and pain scores among treated patients.
Allogeneic cell therapy, a cornerstone of the company's research, involves using donated cells from a healthy individual to treat patients with otherwise intractable diseases. These therapies have shown great potential in providing curative options where traditional treatments have failed.
Creative Medical Technology is heavily involved in multiple clinical trials and continues to secure necessary regulatory approvals. The company’s financial health remains robust, with significant cash reserves and no long-term debt. Furthermore, Creative Medical Technology has built a strong intellectual property portfolio with over 68 patents and pending applications.
As of the latest updates, the FDA has cleared the company to proceed with a Phase 1/2 clinical trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for chronic lower back pain. The IRB approval has been received, paving the way for a placebo-controlled study that will assess the safety, efficacy, and tolerability of the treatment.
Overall, Creative Medical Technology Holdings is poised at the forefront of regenerative medicine, leveraging cutting-edge stem cell technologies to develop transformative therapies for chronic and debilitating conditions. The company’s ongoing clinical trials and strategic partnerships underline its commitment to medical innovation and improving patient outcomes globally.
Creative Medical Technology Holdings (OTC – CELZ) has announced the launch of its second Regenerative Immunology product, MyeloCelz™, which focuses on utilizing the innate immune system to promote healing. This innovative approach complements the existing ImmCelz™ product, which activates the body’s stem cells primarily through T and B cells. With a focus on personalized therapy, MyeloCelz™ aims to enhance safety and efficacy. The company’s products are backed by comprehensive patent applications, highlighting its commitment to advancing immunotherapy for degenerative conditions.
Creative Medical Technology Holdings (CELZ) has appointed Dr. Courtney Bartlett to lead clinical development for its therapeutic products. Dr. Bartlett brings a decade of experience in cell and gene therapy, having contributed to high-profile stem cell trials. She will prioritize collaborating with the FDA to secure Investigational New Drug application clearance for upcoming stroke treatment trials. The company's existing products, including Caverstem® and StemSpine®, show clinical promise as it aims to expand its pipeline in regenerative medicine.
Creative Medical Technology Holdings (OTC - CELZ) announced its virtual presentation at the World Stem Cell Summit on June 17, 2021, at 12:00pm EST. The session will include a 20-minute presentation followed by a Q&A session moderated by a representative from Noble Capital Markets. Interested participants can register for free at channelchek.com. The presentation will highlight the company's ImmCelz® subsidiary and is part of a broader initiative to foster biomedical research and investment in regenerative medicine.
Creative Medical Technology Holdings (CELZ) has filed a provisional patent application for its ImmCelz® personalized cell therapy product, demonstrating its potential to suppress autoimmune diabetes. Recent experiments revealed that ImmCelz® enhances the effects of BCG and GM-CSF in preventing diabetes by increasing myeloid suppressor cell activity. The company's focus on innovative immunological pathways is expected to strengthen its intellectual property during the FDA approval process. ImmCelz® has also shown promising results in preclinical models related to various medical conditions.
Creative Medical Technology Holdings (CELZ) announced promising preclinical data suggesting ImmCelz® could treat Parkinson's Disease. Using the MPTP mouse model, ImmCelz® inhibited Parkinsonism-like behavior and protected dopamine cells, enhancing interleukin-10 levels. With over 1 million Parkinson's patients in the USA, this innovation represents a significant market opportunity. The company aims to advance its lead indication, stroke, and address FDA comments before initiating human trials. Overall, this expansion could bolster CELZ's product pipeline in regenerative immunotherapy.
Creative Medical Technology Holdings announced the recruitment of Dr. Camillo Ricordi to its Scientific Advisory Board. Dr. Ricordi will work alongside esteemed advisors to advance the ImmCelz® Regenerative Immunotherapy platform, currently seeking FDA clearance for IND # 27375 to treat stroke. The company has already made strides with its CaverStem® Procedure for erectile dysfunction and has proof of concept for its StemSpine® and OvaStem® treatments. Dr. Ricordi is recognized for his pioneering work in regenerative medicine and stem cell therapies.
Creative Medical Technology Holdings (CELZ) announced receipt of detailed correspondence from the FDA regarding IND #27375 for its ImmCelz® regenerative immunotherapy targeting stroke treatment. This innovative therapy employs a patient's own reprogrammed blood cells, demonstrating effectiveness in animal models for various conditions, including heart and kidney failure. The company's leadership expressed gratitude for the FDA's constructive feedback, essential for the IND proposal's progression. This marks a significant step in their journey towards obtaining regulatory approval for a pioneering treatment.
Creative Medical Technology Holdings (OTC: CELZ) plans to launch Virtual Physician™, a telehealth platform for regenerative medicine, this summer. The platform aims to educate, recruit, and retain patients for their proprietary procedures, such as CaverStem® for erectile dysfunction and FemCelz® for vaginal rejuvenation. As additional products like StemSpine® are commercialized, the platform will expand. The initiative is expected to create shareholder value through a Management Service Organization model, royalties from product promotions, and direct sales of ancillary products.
Creative Medical Technology Holdings (OTC: CELZ) announced the FDA issued IND Number 27375 for its clinical trial using ImmCelz® to treat stroke victims. ImmCelz® utilizes stem cells to reprogram immune cells, enhancing their regenerative capabilities. This milestone is seen as a significant step for the company as it moves toward clinical application. Timothy Warbington, President and CEO, expressed optimism about progressing with the FDA. The company specializes in regenerative medicine across various fields including immunotherapy and neurology.
Creative Medical Technology Holdings (OTC: CELZ) has initiated the recruitment of clinical sites for its StemSpine® procedure, aimed at treating Degenerative Disc Disease (DDD). This patented regenerative stem cell procedure has shown significant efficacy, reporting an 85% reduction in pain over 12 months from a baseline of 8.9. The company plans to geographically disperse sites across the USA to maximize patient access. The first 100 patients will be monitored at intervals of 30 days, 6 months, and 12 months, with results set for publication in a peer-reviewed journal.
FAQ
What is the current stock price of Creative Med Technology Hldgs (CELZ)?
What is the market cap of Creative Med Technology Hldgs (CELZ)?
What does Creative Medical Technology Holdings, Inc. specialize in?
What is CaverStem?
What is AlloStem™?
What are the latest developments in Creative Medical Technology's clinical trials?
How does allogeneic cell therapy work?
What is the company's financial condition?
How is the company contributing to pain management?
What are some of the company's key partnerships?
Where is Creative Medical Technology Holdings located?
What is the ticker symbol for Creative Medical Technology Holdings, Inc.?
